1407495-02-6

1407495-02-6 structure
1407495-02-6 structure
  • Name: Bococizumab
  • Chemical Name: Bococizumab
  • CAS Number: 1407495-02-6
  • Molecular Formula:
  • Molecular Weight:
  • Catalog: Signaling Pathways Metabolic Enzyme/Protease Ser/Thr Protease
  • Create Date: 2022-10-10 17:25:17
  • Modify Date: 2024-04-06 01:19:06
  • Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia[1][2].

Name Bococizumab
Description Bococizumab (PF-04950615) is an anti-human PCSK9 inhibitory antibody that reduces LDL cholesterol levels. Bococizumab can be used in the research of hypercholesterolemia[1][2].
Related Catalog
Target

PCSK9[1]

In Vivo Bococizumab (0-100 mg/kg, i.v.) decreases maternal and fetal cholesterol and does not affect rat embryo-fetal development[2]. Animal Model: Pregnant Sprague-Dawley (SD) rats[1] Dosage: 0, 10, 30, and 100 mg/kg Administration: Intravenous injection (i.v.) Result: Decreased in fetal cholesterol levels. Showed well tolerance and no effects on ovarian or uterine parameters.
References

[1]. Koutaro Yokote, et al. Efficacy and Safety of Bococizumab (RN316/PF-04950615), a Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, in Hypercholesterolemic Japanese Subjects Receiving a Stable Dose of Atorvastatin or Treatment-Naive - Results From a Randomized, Placebo-Controlled, Dose-Ranging Study. Circ J. 2017 Sep 25;81(10):1496-1505.

[2]. Sarah N Campion, et al. Decreased maternal and fetal cholesterol following maternal bococizumab (anti-PCSK9 monoclonal antibody) administration does not affect rat embryo-fetal development. Regul Toxicol Pharmacol. 2015 Nov;73(2):562-70.

No Any Chemical & Physical Properties
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.